Garrido A, Lepe J A, Guerrero F J, Palomo S
Unidad de Digestivo, Hospital Comarcal de Riotinto, Huelva.
Enferm Infecc Microbiol Clin. 2000 Dec;18(10):512-5.
Serologic response of patients with chronic hepatitis C (CHC) was studied as a predictor of response to IFN therapy and we evaluated the correlation between such response with gender, risk factor, serum ferritin, GGT, Knodell's index and fibrosis.
A study was carried out in 40 patients with CHC who were treated with interferon-alpha 3 MU 3 times weekly 48 weeks. The diagnosis of hepatitis C was made based upon Inmuno-Blot (core, NS3, NS4 y NS5) and confirmed by detection of HCV-RNA in serum. Responses were evaluated (normal ALT and undetectable HCV-RNA in serum) at three months, at the end of treatment and six months after treatment.
No significant differences were observed in responses at three months with regard to gender (47% males responded versus 55% females, n.s.), source of infection (50% intravenous drug users versus 50% non intravenous drug users; n.s.) and GGT level (50% with high levels versus 50% with normal levels, n.s.); however 25% of patients with high level of serum iron responded versus 59% with normal values (p = 0.04) and 28% of patients with fibrosis at liver histopathology responded versus 82% without fibrosis (p = 0.0006). No differences were observed at the response rates with regard to levels of core (20.1 SD:4 versus 19.5 SD:2.2, n.s.), NS3 (18.6 SD:7 versus 17.1 SD:7.3, n.s.) and NS4 (14.3 SD:7.7 versus 10.5 SD:9.2, n.s.). However NS5 levels in responders were 2.5 (0-16) versus 5.2 (0-16.5) in nonresponders (p < 0.05) and score in Knodell's index was 6.1 SD:2.6 in responders versus 9.2 SD:2.4 in nonresponders (p = 0.006). 47% of responders relapsed 6 months after the end of treatment with IFN.
Titers of anti-NS5 showed predictive value of response as opposed to anti-core, anti-NS3 and anti-NS4 and it may justify its determination in the assessment of a patient with CHC at centers without capacity for measuring genotype and viral load. Low level of serum iron and Knodell's index like absence of fibrosis at liver histopathology were also variables with predictive value of response, as opposed to gender, GGT level and source of infection.
研究慢性丙型肝炎(CHC)患者的血清学反应,以此作为干扰素治疗反应的预测指标,并评估该反应与性别、危险因素、血清铁蛋白、谷氨酰转肽酶(GGT)、Knodell指数及肝纤维化之间的相关性。
对40例CHC患者进行研究,这些患者接受α干扰素3 MU,每周3次,共48周的治疗。丙型肝炎的诊断基于免疫印迹法(核心抗原、NS3、NS4和NS5),并通过血清中HCV-RNA的检测得以确认。在治疗3个月时、治疗结束时及治疗后6个月评估反应情况(血清谷丙转氨酶(ALT)正常且HCV-RNA检测不到)。
在治疗3个月时,就性别而言(47%的男性有反应,女性为55%,无显著差异)、感染源(50%的静脉吸毒者有反应,50%的非静脉吸毒者有反应;无显著差异)及GGT水平(50%的高水平者有反应,50%的正常水平者有反应,无显著差异),未观察到显著差异;然而,血清铁水平高的患者中有25%有反应,而血清铁水平正常的患者中有59%有反应(p = 0.04),肝组织病理学有纤维化的患者中有28%有反应,而无纤维化的患者中有82%有反应(p = 0.0006)。就核心抗原水平(20.1标准差:4 vs 19.5标准差:2.2,无显著差异)、NS3水平(18.6标准差:7 vs 17.1标准差:7.3,无显著差异)和NS4水平(14.3标准差:7.7 vs 10.5标准差:9.2,无显著差异)而言,反应率未观察到差异。然而,有反应者的NS5水平为2.5(0 - 16),无反应者为5.2(0 - 16.5)(p < 0.05),Knodell指数评分在有反应者中为6.1标准差:2.6,在无反应者中为9.2标准差:2.4(p = 0.006)。47%的有反应者在干扰素治疗结束后6个月复发。
与抗核心抗原、抗NS3和抗NS4相反,抗NS5滴度显示出反应的预测价值,这可能证明在没有检测基因型和病毒载量能力的中心,对CHC患者进行评估时测定抗NS5是合理的。血清铁水平低和Knodell指数以及肝组织病理学无纤维化,与性别、GGT水平和感染源相反,也是具有反应预测价值的变量。